Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ICML 2019 | CheckMate 205 study of nivo plus AVD in cHL: 2-year follow-up

Stephen Ansell • 2 Jul 2019
ICML 2019
Hodgkin Lymphoma Lymphoma Antibodies Checkpoint inhibitors Nivolumab
CheckMate 205

Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, gives an update on the 2-year follow-up of cohort D of the CheckMate 205 study (NCT02181738), which investigated pembrolizumab for the treatment of classical Hodgkin lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Stephen Ansell

Lymphovision: an AI model for histology-based lymphoma classification and subtyping 1:45
Lymphovision: an AI model for histology-based lymphoma classification and subtyping
Stephen Ansell • 5 Dec 2025
Advances in Hodgkin lymphoma: novel treatments and innovative methods to measure efficacy 1:25
Advances in Hodgkin lymphoma: novel treatments and innovative methods to measure efficacy
Stephen Ansell • 5 Dec 2025
Mantle cell lymphoma: frontline therapy, the role of autoSCT, the value of MRD, & more 15:05
Mantle cell lymphoma: frontline therapy, the role of autoSCT, the value of MRD, & more
Michael Wang et al. • 27 Sep 2025
How the Hodgkin lymphoma treatment landscape is evolving & future directions 1:09
How the Hodgkin lymphoma treatment landscape is evolving & future directions
Stephen Ansell • 19 Jun 2025

Related Videos

A retrospective study of Pola-R-CHP versus R+DA-EPOCH in high-risk DLBCL 1:58
A retrospective study of Pola-R-CHP versus R+DA-EPOCH in high-risk DLBCL
Rahul Thakur • 8 Dec 2025
Glofitamab-GemOx versus R-GemOx in transplant-ineligible R/R DLBCL: subgroup analysis of STARGLO 2:24
Glofitamab-GemOx versus R-GemOx in transplant-ineligible R/R DLBCL: subgroup analysis of STARGLO
Haifaa Abdulhaq • 8 Dec 2025
Epcoritamab + R2 or epcoritamab maintenance in 1L FL: 3-year outcomes from EPCORE NHL-2 arms 6 & 7 2:53
Epcoritamab + R2 or epcoritamab maintenance in 1L FL: 3-year outcomes from EPCORE NHL-2 arms 6 & 7
Lori Leslie • 7 Dec 2025
Extended follow-up from a Phase I/II study of golcadomide ± rituximab in patients with R/R DLBCL 1:35
Extended follow-up from a Phase I/II study of golcadomide ± rituximab in patients with R/R DLBCL
Marc Hoffman • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals